Environment
AI voice test shows promise for type 2
An AI tool can detect type 2 diabetes from 20-second voice recordings with 80% accuracy, offering a potential new non-invasive screening method to identify
Environment
Environment on Night and Rest: Compartir cama.
Environment
Fenoterol study reveals obesity drug
A University of Basel study found the drug fenoterol increased energy expenditure in 11 volunteers but did not activate brown fat, suggesting a more
Environment
Study Links Micro-Awakenings to Alzheimer's Genetic Risk
Research on over 500 people finds a higher frequency of brief nocturnal micro-awakenings in middle-aged adults is associated with a greater genetic risk
Environment
NIH Grant Funds At-Home VortexPAP Development
NIH awarded AcouFlow Therapeutics a grant to develop a home version of its VortexPAP device, aiming to improve CPAP adherence with a seal-less mask.
Environment
VR vision training may slow childhood myopia
A study published in JAMA Ophthalmology found that children using virtual reality-based digital defocus vision training for 15 minutes daily showed slower
Environment
ESC releases first cardiac rehab guidelines
The European Society of Cardiology's first cardiac rehab guidelines emphasize its physical and mental health benefits and note its underuse in Europe.
Environment
Cancer Drug May Treat Chronic Nerve Pain
A preclinical study from MD Anderson Cancer Center suggests existing BRAF inhibitor cancer drugs could be repurposed to treat chronic nerve pain by
Environment
The Role of Mechanical Forces in Cell Biology
Research by Sara Wickström has shown that cells are not only influenced by chemical signals, but also by mechanical forces, which can affect gene expression and cell behavior.
Environment
ICER Report Evaluates Clinical Value of New Narcolepsy Type 1 Treatment
The Institute for Clinical and Economic Review (ICER) has published a final evidence report on oveporexton, a novel orexin receptor 2 agonist for narcolepsy type 1 (NT1). The drug received a B+ rating compared to no treatment and a C++ rating against active comparators. ICER suggests a benchmark price of $50,400 to $59,400 per year for the therapy, which has since gained FDA approval.